Investors
2022 Financial Results
- Strong sales growth in the fourth quarter:
- Organic growth of 5.9%
- Very high demand for respiratory panels within the “tripledemic” (Flu/Covid/RSV) context
- Remarkable growth in non-respiratory panels and Industrial Applications
- Strong performance in 2022 with robust full-year sales and 18.5% contributive operating margin, above initial expectations
- Confirmed 2023 guidance
“In 2022, bioMérieux achieved a solid performance and adjusted upward its guidance during the year. The year has been marked by the acquisition of Specific Diagnostics which reinforces our product offering and our long-standing commitment to the fight against antimicrobial resistance. 2022 has been also an intense year in R&D and launch of several new platforms that will contribute to strengthen our market positions and sustain our growth”